No retraction, correction or concern found when last checked on Nov 2, 2026.

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

Charlotte Van Den Berg, Colette Smit, Giel Van Brussel and 2 more

Addiction · 2007

doi:10.1111/j.1360-0443.2007.01912.x

Abstract

Objectives To investigate the impact of harm‐reduction programmes on HIV and hepatitis C virus (HCV) incidence among ever‐injecting drug users (DU) from the Amsterdam Cohort Studies (ACS). Methods The association between use of harm reduction and seroconversion for human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV) was evaluated using Poisson regression. A total of 714 DU were at risk for HIV and/or HCV during follow‐up. Harm reduction was measured by combining its two most important components—methadone dose and needle exchange programme (NEP) use—and looking at five categories of participation, ranging from no participation (no methadone in the past 6 months, injecting drug use in the past 6 months and no use of NEP) to full participation (≥ 60 mg methadone/day and no current injecting or ≥ 60 mg methadone/day and current injecting but all needles exchanged). Results Methadone dose or NEP use alone were not associated significantly with HIV or HCV seroconversion. However, with combination of these variables and after correction for possibly confounding variables, we found that full participation in a harm reduction programme (HRP) was associated with a lower risk of HIV and HCV infection in ever‐injecting drug users (DU), compared to no participation [incidence rate ratio 0.43 (95% CI 0.21–0.87) and 0.36 (95% CI 0.13–1.03), respectively]. Conclusions In conclusion, we found that full participation in HRP was associated with a lower incidence of HCV and HIV infection in ever‐injecting DU, indicating that combined prevention measures—but not the use of NEP or methadone alone—might contribute to the reduction of the spread of these infections.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 23

1.
Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42-6.
Not in our library10.2105/ajph.91.1.42
2.
Buning EC, Coutinho RA, van Brussel GH, van Santen GW, van Zadelhoff AW. Preventing AIDS in drug addicts in Amsterdam. Lancet. 1986;1:1435.
Not in our library10.1016/s0140-6736(86)91570-9
3.
Langendam MW, van Brussel GH, Coutinho RA, Van Ameijden EJ. Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study. Addiction. 2000;95:591-600.
Not in our library10.1046/j.1360-0443.2000.95459110.x
4.
Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS. 1998;12:S217-30.
Not in our library
5.
Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777-813.
Not in our library10.1080/10826080600669579
6.
What Is the Evidence for the Effectiveness of Interventions to Reduce Hepatitis C Infection and the Associated Morbidity? 2005.
Not in our library
7.
Lindenburg CEA, Krol A, Smit C, Buster MC, Coutinho RA, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS. 2006;20:1771-5.
Not in our library10.1097/01.aids.0000242824.59377.53
8.
Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K, et al. Sexual transmission of HCV between spouses. Am J Gastroenterol. 2005;100:821-4.
Not in our library10.1111/j.1572-0241.2005.40879.x
9.
Terrault NA. Sex and hepatitis C. Am J Gastroenterol. 2005;100:825-6.
Not in our library10.1111/j.1572-0241.2005.41807.x
10.
van den Hoek JAR, Coutinho RA, van Haastrecht HJA, van Zadelhoff AW, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS. 1988;2:55-60.
Not in our library10.1097/00002030-198802000-00010
11.
Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025-9.
Not in our library
12.
Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321-9.
Not in our library10.1016/j.jsat.2005.02.007
13.
Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100:1496-509.
Not in our library10.1111/j.1360-0443.2005.01232.x
14.
van den Berg CHSB, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22:183-93.
Not in our library10.1007/s10654-006-9089-7
15.
Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, Gonzalez-Aracil J, Perez-Hoyos S, de la Hera MG. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17:539-44.
Not in our library10.1023/a:1014560431726
16.
Muga R, Sanvisens A, Bolao F, Toi J, Santesmases J, Pujol R, et al. Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987–2001. Drug Alcohol Depend. 2006;82:S29-33.
Not in our library10.1016/s0376-8716(06)80005-0
17.
Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS. 1998;12:2059-66.
Not in our library10.1097/00002030-199815000-00018
18.
MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Kaldor JM. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Med J Aust. 2000;172:57-61.
Not in our library10.5694/j.1326-5377.2000.tb139199.x
19.
Somaini B, Wang J, Perozo M, Kuhn F, Meili D, Grob P, et al. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care. 2000;12:449-60.
Not in our library10.1080/09540120050123855
20.
Taylor A, Goldberg D, Hutchinson S, Cameron S, Gore SM, McMenamin J, et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990–1996: are current harm reduction strategies working? J Infect. 2000;40:176-83.
Not in our library10.1053/jinf.2000.0647
21.
Langendam MW, van Haastrecht HJ, Van Ameijden EJ. The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities. Int J Epidemiol. 1999;28:514-20.
Not in our library10.1093/ije/28.3.514
22.
Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18:2295-303.
Not in our library10.1097/00002030-200411190-00010
23.
Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet. 2003;361:1035-44.
Not in our library10.1016/s0140-6736(03)12831-0

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.